Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Artery-Saving surgery may reduce complications after esophageal cancer removal

NCT ID NCT07363629

Disease control Sponsor: The First Hospital of Hebei Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 120 people with esophageal cancer who had a type of surgery called McKeown esophagectomy. Half had the right gastric artery preserved, and half had it tied off. The goal was to see if preserving the artery lowers the chance of leaks or narrowing where the new connection is made. Results could help surgeons choose the safer approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
surgical procedure (right gastric artery preservation or ligation during McKeown esophagectomy)
What this could lead to
If preserving the artery works better, it could reduce serious complications like leaks or narrowing after esophageal cancer surgery, improving recovery.
What could go wrong
This is a single-center trial with 120 people, so results may not apply to all patients. The benefit may be small or not outweigh the risk of leaving the artery intact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Jun 2018

Finished

Nov 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed squamous cell carcinoma of the middle or upper thoracic esophagus. * Candidates for elective McKeown minimally invasive esophagectomy (MIE). * Age 18-75 years. * Preoperative clinical stage I-IIIA (cT1-3N0-1M0) according to the AJCC/UICC 8th Edition TNM staging system. Exclusion Criteria: * Clinical stage IIIB or IV. * History of previous thoracic or abdominal surgery affecting the stomach or esophagus. * Neoadjuvant chemoradiotherapy (to eliminate confounding effects on tissue healing). * Severe comorbidities (e.g., uncontrolled diabetes, severe cardiopulmonary dysfunction, liver cirrhosis). * Intraoperative finding of unresectable tumor. * Conversion to open surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal squamous cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal squamous cell carcinoma

Contacts and locations

Locations

  • Hebei General Hospital

    Shijiazhuang, Hebei, 050000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.